A European training network for the discovery of neurotrophins small molecule mimetics as candidate therapeutic agents for neurodegeneration and neuroinflammation
Total Cost €
0
EC-Contrib. €
0
Partnership
0
Views
0
EuroNeurotrophin project word cloud
Explore the words cloud of the EuroNeurotrophin project. It provides you a very rough idea of what is the project "EuroNeurotrophin" about.
Neurodegenerative diseases (ND) like AD, PD, MS and ALS/MND are on the rise in developed societies worldwide. Currently, there exists no cure for any ND, and most of the available drugs fail to tackle ND pathogenesis. Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive.
The key idea behind this project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. We are motivated by seminal (patented) results of beneficiaries NHRF and FORTH, who recently demonstrated promising effects of small neurotrophin mimetics in neuroprotection and neurogenesis. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation.
This approach requires highly skilled researchers that have a deep understanding of neurotrophins, comprehend all steps of drug discovery and development for ND, and possess the necessary skills to translate results into novel therapies.
The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It builds on previous successful collaborations enriched with key specialists, and consists of 12 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively we will (a) conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and (b) accelerate the translation of identified drug candidate molecules into the market.
Publications
year
authors and title
journal
last update
List of publications.
2020
Athanasios Ziogas, Tomoki Maekawa, Johannes R. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis, Vasileia Ismini Alexaki DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1 published pages: 1214-1224, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900746
The Journal of Immunology 204/5
2020-03-11
2019
Canelif Yilmaz, Kanelina Karali, Georgia Fodelianaki, Achille Gravanis, Triantafyllos Chavakis, Ioannis Charalampopoulos, Vasileia Ismini Alexaki Neurosteroids as regulators of neuroinflammation published pages: 100788, ISSN: 0091-3022, DOI: 10.1016/j.yfrne.2019.100788
Frontiers in Neuroendocrinology 55
2020-03-11
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EURONEUROTROPHIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "EURONEUROTROPHIN" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.1.3.1.)